Edgestream Partners, L.P. Madrigal Pharmaceuticals, Inc. Transaction History

Edgestream Partners, L.P.

  • $2.23 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$120.4 - $237.13 $69,832 - $137,535
-580 Reduced 37.01%
987 $228,000
Q3 2023

Nov 14, 2023
SELL
$146.04 - $225.78 $146,478 - $226,457
-1,003 Reduced 39.03%
1,567 $228,000
Q2 2023

Aug 10, 2023
BUY
$203.88 - $312.0 $523,971 - $801,840
2,570 New
2,570 $593,000

Others Institutions Holding MDGL

# of Institutions
296
Shares Held
22M
Call Options Held
819K
Put Options Held
640K
View Full List

About MADRIGAL PHARMACEUTICALS, INC.

MDGL Quotes by TradingView
  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.94B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Edgestream Partners, L.P. Portfolio

Follow Edgestream Partners, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Edgestream Partners, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email